ArticleBiosafety and health2026
Systematic optimization of a domestic nose-only aerosol exposure system for respiratory pathogen research in nonhuman primates.
Article in Biosafety and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imported aerosol exposure systems for nonhuman primates are often costly and limited in availability, restricting advanced research on respiratory pathogens. To address this, a domestically developed nose-only aerosol exposure system was systematically evaluated and optimized to enhance performance and accessibility. Comprehensive assessment of aerosol generation, transmission, and sampling components revealed key areas for improvement, which were targeted through four modifications: adoption of a vibrating mesh nebulizer for physiologically relevant particle sizes, reduction of plenum chamber volume to minimize losses, shortening of transmission pathways, and addition of 0.25% newborn calf serum to sampling media for viral preservation. These changes collectively minimized viral viability loss during aerosol delivery. The optimizations resulted in a 2.19 log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.